Release Date: May 31, 2018
Expiration Date: May 31, 2019
Media: Internet - based
For the first time in decades, treatment options for patients with systemic lupus erythematosus (SLE) are expanding, offering patients new hope for living a longer, healthier life and reducing the burden of disease. With these advances, active lupus is no longer the leading cause of morbidity and mortality. Patients are now facing significant morbidity from potentially preventable conditions and clinicians must learn how to address these new problems through improved preventive care and treatment of lupus flares. During this Medical Crossfire®, expert faculty will engage in a multidisciplinary roundtable discussion that includes a rheumatologist, dermatologist, and nurse practitioner. The panel provides key guidance for identifying and treating lupus flares, improving preventive care, and engaging patients in treatment decisions in order to improve their treatment adherence. The safety and efficacy of new and emerging treatments will also be addressed so that clinicians are prepared to provide their patients with the most up-to-date treatment options.
Instructions for This Activity and Receiving Credit
This CME activity is intended for rheumatologists, primary care providers, nurse practitioners (NPs), physician assistants, nurses, and other health care professionals who treat patients with SLE.
Upon completion of this CME activity, you should be better prepared to:
Paul P. Doghramji, MD, FAAFP
Collegeville Family Practice
Medical Director, Health Services
Disclosure: Paul P. Doghramji, MD, FAAFP has no financial information to disclose.
Amy X. Ma, DNP, FNP-BC
Harriet Rothkopf Heilbrunn School of Nursing
Long Island University – Brooklyn
FIT Health Service
New York, New York
Disclosure: Amy X. Ma, DNP, FNP-BC has no financial information to disclose.
Maureen McMahon, MD, MS
Associate Professor of Medicine/Rheumatology
UCLA David Geffen School of Medicine
Division of Rheumatology
Los Angeles, California
Disclosure: Maureen McMahon, MD, MS - Consulting: AstraZeneca, GlaxoSmithKline
Victoria P. Werth, MD
Department of Dermatology and Medicine (Rheumatology)
University of Pennsylvania School of Medicine
Disclosure: Victoria P. Werth, MD - Grant/Research Support: Celgene, Janssen, Pfizer, Biogen, Corbus Pharmaceuticals, LuCIN, Genentech, Syntimmune, AstraZeneca
Consulting: Celgene, Medimmune, Resolve, Neovcs, ACI, Immune Pharmaceuticals, Genentech, Idera, Octapharma, BSL Behring, Janssen, Lilly, Pfizer, Biogen, Bristol-Myers Squibb, Biostrategies, Gilead, Amgen, Medscape, Principia, Nektar, Syntimmune, Incyte, EMD Sorona
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and is a provider approved by the California Board of Registered Nursing (CBRN).
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019